Get the Stockscreener App
54.35
11.97%
5.81
Moderna Inc stock is traded at $54.35, with a volume of 20.76M.
It is up +11.97% in the last 24 hours and up +4.32% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$48.54
Open:
$49
24h Volume:
20.76M
Relative Volume:
2.58
Market Cap:
$21.57B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-6.6718
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
+19.79%
1M Performance:
+4.32%
6M Performance:
+121.48%
1Y Performance:
+122.93%
1-Day Range:
$48.98
$57.78
1-Week Range:
$45.29
$57.78
52-Week Range:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
54.35 | 21.57B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
MRNA stock clocks best day in over two months on early-stage hantavirus vaccine research - MSN
MRNA Stock Clocks Best Day In Over Two Months On Early-Stage Hantavirus Vaccine Research - Stocktwits
[Form 4] Moderna, Inc. Insider Trading Activity - Stock Titan
Moderna (MRNA) Gains Attention Amid Rising Virus Concerns - GuruFocus
MRNA Stock Alert: Moderna Surges on Hantavirus Vaccine Hopes - Yahoo Finance
Moderna (MRNA) Shares Skyrocket, What You Need To Know - TradingView
Moderna Stock Surges on Hantavirus Vaccine News as Cruise Outbreak Puts mRNA Pipeline Back in Focus - TechStock²
Moderna (MRNA) Advances Hantavirus Vaccine Development Amid Rene - GuruFocus
Moderna stock surges on hantavirus vaccine research confirmation - Investing.com
Moderna Accelerates Hantavirus Vaccine Research Amid Cruise Outbreak - AsatuNews.co.id
How Hantavirus Made Moderna a Must-Own Stock Again - Barron's
Top Biotech Stocks To Follow NowMay 8th - MarketBeat
What's Going On With Novavax Stock On Friday?Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX) - Benzinga
Moderna flags work on hantavirus vaccines before cruise outbreak - The Boston Globe
Moderna jumps on word it is working on a hantavirus vaccine - Seeking Alpha
Moderna (NASDAQ:MRNA) Trading 12.6% HigherShould You Buy? - MarketBeat
Moderna (MRNA) Stock Surges 16% on Flu Vaccine Data and Analyst Upgrades - CoinCentral
Moderna Flags Work on Hantavirus Vaccines Before Cruise Outbreak - Bloomberg.com
[144] Moderna, Inc. SEC Filing - Stock Titan
Why is Moderna stock surging today? By Investing.com - Investing.com Canada
Moderna Stock Rises On Positive Phase 3 Flu Data: What Investors Need To Know - Benzinga
Moderna Stock Climbs After Hantavirus Vaccine: Data Triggers Analyst Price Target - Investing.com
Moderna Inc. stock (US60770K1034): Shares rebound after earnings and strong 2026 run-up - AD HOC NEWS
Moderna Stock Climbs After Hantavirus Vaccine: Data Triggers Analyst Price Target Hikes - Tokenist
CHINA SHOTO : 9000 Leverage Shares 3x Long Moderna (MRNA) ETP Securities - marketscreener.com
Gateway Investment Advisers LLC Acquires 131,364 Shares of Moderna, Inc. $MRNA - MarketBeat
5 Insightful Analyst Questions From Moderna’s Q1 Earnings Call - The Globe and Mail
Moderna (MRNA) Stock Surges on Hantavirus Outbreak News, Analysts Warn of Speculation - GuruFocus
MRNA Stock Quote Price and Forecast - CNN
Hantavirus: What to Know About the Virus—and Why Moderna Stock Rallied - Barron's
Investors Buy Large Volume of Moderna Call Options (NASDAQ:MRNA) - MarketBeat
Moderna Stock Rallied on Hantavirus Fears. What to Know. - Barron's
Moderna stock holds steady amid regulatory review of mRNA-1010 in US, EU, Canada, Australia - Traders Union
Moderna stock jumps 10% amid hantavirus outbreak concerns By Investing.com - Investing.com Canada
Brookline Capital Markets Forecasts Moderna FY2026 Earnings - MarketBeat
NVAX Stock Eyes Breakout Week: Novavax Claims Patients Were ‘Twice As Likely’ To Pick Its COVID Shot Over Moderna Again - Stocktwits
MRNA SEC FilingsModerna 10-K, 10-Q, 8-K Forms - Stock Titan
Moderna Shareholders OK Directors, Executive Pay Votes and Ernst & Young as 2026 Auditor at AGM - Yahoo Finance
Is Wall Street Bullish or Bearish on Moderna Stock? - Yahoo Finance
Moderna flu vaccine shows superior efficacy in phase 3 study By Investing.com - Investing.com Australia
Moderna flu vaccine shows superior efficacy in phase 3 study - Investing.com
Moderna's flu shot heads to FDA decision after NEJM Phase 3 data - Stock Titan
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 - Weatherford Democrat
Moderna's mRNA flu vaccine outperforms standard shot in late-stage trial - Reuters
Moderna's mRNA flu vaccine is more effective than the standard shot in a late-stage trial - AOL.com
MRNA Stock Price, Quote & Chart | MODERNA INC (NASDAQ:MRNA) - ChartMill
Moderna stands as the best performing large-cap healthcare stock YTD - MSN
FDA halts publication of studies on COVID, shingles vaccines - Seeking Alpha
Brookline Capital Markets Weighs in on Moderna Q2 Earnings - MarketBeat
Non-covid mRNA Vaccine and Therapeutics Market Supply Chain Analysis and Revenue Forecast 2026 to 2035 - openPR.com
Moderna (MRNA) Receives a Buy from Piper Sandler - The Globe and Mail
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.48%
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):